Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?

doi:10.1093/cid/ciaa321

Comment

. 2020 Jul 28;71(15):888-889.

doi: 10.1093/cid/ciaa321.

Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?

Maurizio Guastalegname¹, Alfredo Vallone¹

Affiliations

PMID: 32211771
PMCID: PMC7184345
DOI: 10.1093/cid/ciaa321

Comment

Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?

Maurizio Guastalegname et al. Clin Infect Dis. 2020.

. 2020 Jul 28;71(15):888-889.

doi: 10.1093/cid/ciaa321.

Authors

Maurizio Guastalegname¹, Alfredo Vallone¹

Affiliation

¹ Infectious Diseases Unit, Jazzolino Hospital, Vibo Valentia, Italy.

PMID: 32211771
PMCID: PMC7184345
DOI: 10.1093/cid/ciaa321

No abstract available

PubMed Disclaimer

Comment on

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D. Yao X, et al. Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237. Clin Infect Dis. 2020. PMID: 32150618 Free PMC article.

Cited by

A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.
Sharun K, Tiwari R, Yatoo MI, Natesan S, Megawati D, Singh KP, Michalak I, Dhama K. Sharun K, et al. Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8. Narra J. 2022. PMID: 38449903 Free PMC article. Review.
Impact of prophylactic hydroxychloroquine on ultrastructural impairment and cellular SARS-CoV-2 infection in different cells of bronchoalveolar lavage fluids of COVID-19 patients.
Chaudhary S, Joshi A, Sesham K, Rai P, Kumar S, Mridha AR, Baitha U, Nag TC, Yadav SC. Chaudhary S, et al. Sci Rep. 2023 Aug 5;13(1):12733. doi: 10.1038/s41598-023-39941-6. Sci Rep. 2023. PMID: 37543667 Free PMC article.
Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation.
La J, Fillmore NR, Do NV, Brophy M, Monach PA, Branch-Elliman W. La J, et al. Health Res Policy Syst. 2022 Dec 14;20(1):134. doi: 10.1186/s12961-022-00935-x. Health Res Policy Syst. 2022. PMID: 36517793 Free PMC article.
COVID-19 pandemic: A multidisciplinary perspective on the pathogenesis of a novel coronavirus from infection, immunity and pathological responses.
Yi J, Miao J, Zuo Q, Owusu F, Dong Q, Lin P, Wang Q, Gao R, Kong X, Yang L. Yi J, et al. Front Immunol. 2022 Aug 26;13:978619. doi: 10.3389/fimmu.2022.978619. eCollection 2022. Front Immunol. 2022. PMID: 36091053 Free PMC article. Review.
Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment.
Sahin G, Akbal-Dagistan O, Culha M, Erturk A, Basarir NS, Sancar S, Yildiz-Pekoz A. Sahin G, et al. J Pharm Sci. 2022 Oct;111(10):2652-2661. doi: 10.1016/j.xphs.2022.06.004. Epub 2022 Jun 9. J Pharm Sci. 2022. PMID: 35691607 Free PMC article. Review.

See all "Cited by" articles

References

1. Yao X, Ye F, Zhang M, et al. . In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome cor onavirus 2 (SARS-CoV-2). Clin Infect Dis 2020. doi:10.1093/cid/ciaa237 - DOI - PMC - PubMed
1. de Wilde AH, Jochmans D, Posthuma CC, et al. . Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 2014; 58:4875–84. - PMC - PubMed
1. Barnard DL, Day CW, Bailey K, et al. . Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir Chem Chemother 2006; 17:275–84. - PubMed
1. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis 2003; 3:722–7. - PMC - PubMed
1. Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for Chloroquine in the Treatment of Novel Coronavirus Pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43:E019. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources

[1] Yao X, Ye F, Zhang M, et al. . In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome cor onavirus 2 (SARS-CoV-2). Clin Infect Dis 2020. doi:10.1093/cid/ciaa237 - DOI - PMC - PubMed

[2] Yao X, Ye F, Zhang M, et al. . In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome cor onavirus 2 (SARS-CoV-2). Clin Infect Dis 2020. doi:10.1093/cid/ciaa237 - DOI - PMC - PubMed

[3] de Wilde AH, Jochmans D, Posthuma CC, et al. . Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 2014; 58:4875–84. - PMC - PubMed

[4] de Wilde AH, Jochmans D, Posthuma CC, et al. . Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 2014; 58:4875–84. - PMC - PubMed

[5] Barnard DL, Day CW, Bailey K, et al. . Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir Chem Chemother 2006; 17:275–84. - PubMed

[6] Barnard DL, Day CW, Bailey K, et al. . Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir Chem Chemother 2006; 17:275–84. - PubMed

[7] Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis 2003; 3:722–7. - PMC - PubMed

[8] Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis 2003; 3:722–7. - PMC - PubMed

[9] Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for Chloroquine in the Treatment of Novel Coronavirus Pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43:E019. - PubMed

[10] Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for Chloroquine in the Treatment of Novel Coronavirus Pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43:E019. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?

Affiliation

Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?

Authors

Affiliation

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources